Bicara Therapeutics Inc.
BCAX
$22.38
-$0.54-2.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.91% | -32.65% | 25.67% | -75.82% | -19.88% |
| Total Depreciation and Amortization | 79.17% | 26.32% | 0.00% | 26.67% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.75% | 5.18% | 3.18% | 23.55% | 38.40% |
| Change in Net Operating Assets | 166.90% | 264.06% | -137.57% | 142.78% | -545.93% |
| Cash from Operations | 18.33% | -14.28% | 8.94% | 6.41% | -74.36% |
| Capital Expenditure | -466.67% | -- | -- | -- | -400.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.23% | -- | -- | -- | -- |
| Cash from Investing | 65.13% | -- | -- | -- | -400.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,062.84% | 222.96% | -70.65% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,062.84% | 222.96% | -70.65% | 147.18% | -100.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.70% | -940.63% | 7.91% | 10.95% | -109.80% |